Apoptosis in megakaryocytes results in the formation of platelets. The role of apoptotic pathways in platelet turnover and in the apoptotic-like changes seen following platelet activation is poorly understood. ABT-263 (Navitoclax), a specific inhibitor of anti-apoptotic BCL2 proteins, which is currently being evaluated in clinical trials for the treatment of leukemia and other malignancies, induces a dose-limiting thrombocytopenia. In this study, the relationship between BCL2/BCL-X Linhibition, apoptosis and platelet activation was investigated. Exposure to ABT-263 induced apoptosis 
Introduction
All nucleated cells in multicellular organisms are genetically programmed to undergo apoptosis to remove unnecessary or damaged cells from the whole organism. This program has been recognized as the central mechanism of platelet production from megakaryocytes. 1 However, the role of apoptosis in anuclear, mature platelets is less well characterized, with apoptotic-like changes seen in both aging platelets and in the formation of pro-coagulant microparticles following agonist stimulation.
Two main pathways lead to the execution of apoptosis; the extrinsic and the intrinsic, or mitochondrial, pathways. Both converge into the activation of caspases, which are proteases that cleave over 500 cellular targets and induce typical morphological changes associated with apoptosis in nucleated cells. A critical step in the intrinsic pathway is the loss of mitochondrial membrane potential (MMP) and the release of cytochrome c into cytosol, where it triggers the activation of caspase-9. Therefore the release of cytochrome c from mitochondria needs to be tightly regulated: a function that is fulfilled by the BCL2 protein family, which consists of pro-apoptotic and antiapoptotic members that promote or block the release of cytochrome c, respectively. 2, 3 The proapoptotic family members BAX and BAK play an essential role in directly mediating the release of cytochrome c by forming a pore in the outer mitochondrial membrane. Anti-apoptotic BCL2 proteins, including BCL2, BCL-X L , BCL-w, MCL1, and BCL2A1, prevent the activation of BAX and BAK.
Besides their function in regulating mitochondrial cytochrome c release, BCL2 proteins have also been implicated in the regulation of intracellular calcium homeostasis at the endoplasmatic reticulum (ER), possibly by interacting with inositol triphosphate receptors. 4, 5 Owing to their key role the anti-apoptotic BCL2 proteins are attractive targets for anticancer therapy, with several small molecule inhibitors currently in preclinical testing or early clinical trials. 6, 7 role in the clearance of senescent platelets by the mononuclear phagocyte system, receives some support from in vitro investigations that show a time-dependent induction of apoptosis in stored platelet preparations. 18 Furthermore, during storage at 37°C the protein expression of BCL-X L decreases, further indicating a critical anti-apoptotic role for BCL-X L in platelets. 19 Data from knockout mice confirm the importance of BCL-X L in platelet survival, since loss of BCL-X L , but not of BCL2, BCL-w or MCL1 resulted in thrombocytopenia.
14,20
The role of BAX and BAK in platelet apoptosis is less clear. Mason et al concluded that BAK is essential for platelet apoptosis and needs to be inhibited by BCL-X L to prevent apoptosis. During platelet aging, the levels of BCL-X L decrease owing to protein degradation, leading to a reduction in BCL-X L -mediated inhibition of BAK and resulting in apoptosis. 14 The proposed model of the ratio of BCL-X L and BAK as a "molecular clock" may provide a useful explanation of how platelet life span is regulated in vivo. Support for an important role for BCL-X L in the regulation of platelet ageing was provided by the observation that platelets from BCL-X L mutant mice have a life span of 11 hours in vivo, compared with 68 hours in wild type control mice.
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BCL2 proteins also play a role in platelet activation by thrombin. 22 The signaling pathways that distinguish platelet apoptosis and platelet activation are not clearly separated since both have been reported to involve a loss of MMP and externalization of PS. Some studies have addressed this question by comparing platelet activation and apoptosis. [23] [24] [25] Here we investigated the effects of BCL2-inhibition on both platelet apoptosis and activation. We demonstrate that both processes are clearly distinguishable, since apoptosis occurs slowly over hours and results in biochemical and ultrastructural changes that are clearly different from those seen during the more rapid process of agonist-induced activation, which occurs within minutes. Furthermore, we found that inhibition of BCL2 proteins induces an immediate calcium response, which prevents the subsequent responsiveness of platelets to physiological agonists. 
Calcium release assays
Washed platelets were incubated for 2 hours in HBS with or without ABT-263 and z-VAD.fmk before staining with 1 μM Fluo4/AM (Invitrogen) for an additional 30 minutes. The intracellular calcium levels were assessed continuously at a FACScalibur after establishing a stable baseline fluorescence signal for 1 minute. A23187 or ABT-263 was added and fluorescence analyzed for additional 4 minutes.
Thiazole-orange staining
The proportion of reticulated platelets was assessed by staining with thiazole-orange as described previously. 28 Washed platelets were incubated in annexin-buffer (10 mM HEPES, 150 mM NaCl, 5 mM KCl, 1 mM MgCl 2 ,1.8 mM CaCl 2 , pH 7.4) plus 50 ng/ml thiazole-orange and ABT-263 for 2 hours before addition of annexin/APC and analysis by flow cytometry.
Microscopy
For confocal microscopy, washed platelets were allowed to settle on glass coverslips for 30 minutes before fixing for 15 minutes with 4% paraformaldehyde in PBS. Platelets were permeabilized for 10
For personal use only. on October 3, 2017. by guest www.bloodjournal.org From minutes using 0.5% Triton-X 100 in PBS with 3% bovine serum albumin, and incubated with mouse anti-cytochrome c, rabbit anti-active caspase 3 (both from BD Biosciences) or anti-tubulin antibody (Sigma-Aldrich) at 1:500 in PBS with 10% goat serum at 4°C overnight. Coverslips were washed and incubated with goat anti-mouse or rabbit secondary antibody/Alexa546 or Alexa488 (Invitrogen). For staining of actin, following antibody staining, platelets were incubated for 30 minutes with phalloidin/Alexa488 (Invitrogen). Coverslips were mounted and observed using a Zeiss LSM510 confocal microscope with a 63x oil immersion lens, using a 6x zoom. Ultrathin sections for electron microscopy were prepared as described previously 29 and recorded using a Megaview 3 digital camera and iTEM software (Olympus Soft Imaging Solutions) in a Jeol 100-CXII electron microscope (Jeol UK Ltd.).
MMP and cytochrome c release
The loss of MMP was assessed by flow cytometry, staining with 50 nM tetramethylrhodamine ethyl ester (TMRE, Invitrogen) for 10 minutes at 37°C. For live cell imaging, platelets were incubated with 25 nM TMRE and 1:100 CD41/FITC during the 30 minute period of settling onto coverslips, and imaged immediately. To assess the release of mitochondrial cytochrome c, platelets were washed in cold PBS and resuspended at 1 x 10 8 in 30 μl of mitochondrial isolation buffer (250 mM sucrose, 20 mM HEPES, pH 7.4, 5 mM MgCl 2 and 10 mM KCl) containing 0.05% digitonin. Cells were left on ice for 10 minutes followed by centrifugation at 13,000 rpm for 3 minutes. Subsequently, supernatant and pellets were analyzed by western blotting.
Western blotting and immunoprecipitation
For analysis of protein expression, 1x 10 8 platelets were lysed in 0.5% Triton-X 100, 150 mM NaCl, CHAPS before elution in SDS-loading dye and western blotting. Quantification of BAK binding to BCL-X L was performed using ImageJ software.
Statistical Analysis
The EC 50 ( Figure 1) ( Figures 1C-D) . We have previously shown that the presence of albumin decreases the efficacy of both compounds to induce apoptosis of CLL cells, and that ABT-263 has a higher affinity for albumin and is therefore more efficiently sequestered by this plasma protein. 31 To investigate whether the binding of drug to albumin was responsible for the loss of sensitivity in whole blood, we incubated washed platelets in HBS containing 3% human serum albumin (HSA). The addition of albumin resulted in a loss of sensitivity to ABT-737 and ABT-263, confirming that albumin sequesters both drugs. Interestingly, in the case of ABT-737 ( Figure 1C ) the addition of albumin accounted for most of the reduced sensitivity in whole blood, while for ABT-263 ( Figure 1D ) the addition of albumin caused only a partial loss of sensitivity compared to whole blood. These data indicate that other factors in the blood besides albumin binding diminish the efficacy of ABT-263, but not of ABT-737, to induce platelet apoptosis.
ABT-737 and ABT-263 lack selective toxicity in CLL
In initial clinical studies with ABT-263 as a potential anticancer agent, thrombocytopenia is the Taken together these data demonstrate that caspases are essential for platelet apoptosis but not activation. Our data do not exclude that caspase activation or release of cytochrome c may occur at later times following platelet activation, but these events are clearly not required for the initiation of platelet activation.
Platelet apoptosis triggers thrombin generation
The externalization of PS is a common feature of both platelet activation and apoptosis. Since PS exposure on the platelet surface facilitates the formation of the prothrombinase complex, 33 we investigated whether platelets exposed to ABT-263 or ABT-737 promote the generation of thrombin at time points when the PS exposure was clearly evident (2 hours). Although the PS externalization occurred much more slowly ( Figure 1 ), both ABT-737 and ABT-263 induced the generation of thrombin at a faster rate (as indicated by shorter lag times and time to peak) and more strongly (as indicated by a greater level of peak thrombin) than CRP-XL or TRAP and nearly as strongly as A23187 ( Figure 3A ), confirming that the PS exposure during apoptosis triggers the formation of the prothrombinase complex.
Inhibition of BCL2 proteins prevents platelet activation
Incubation of platelets for 2 hours with ABT-263 did not induce surface expression of P-selectin (data not shown). Taken together, these data show that despite PS exposure and thrombin generation, BCL2-inhibition prevents, rather than facilitates, platelet activation.
Inhibition of BCL2 proteins results in a depletion of intracellular calcium
Next, we investigated whether the repression of platelet activation upon BCL2-inhibition was due to a caspase-mediated event. However, addition of the caspase inhibitors z-VAD.fmk or Q-VD-OPh to ABT-263 or ABT-737 did not restore the platelets ability to respond to agonist or calcium ionophore 
Ultrastructural changes during platelet apoptosis
Since the ultrastructural changes during apoptosis of non-nucleated platelets have not been well characterized, we examined platelet morphology following exposure to ABT-737. Resting platelets displayed the typical discoid shape with a diffuse distribution of granules and organelles, whereas platelets exposed to ABT-737 were distended and displayed a peripheral distribution of most granules These changes, together with those observed by electron microscopy, indicate that caspases activated during apoptosis caused a dramatic change in cell morphology clearly distinct from the morphology observed during platelet activation.
BCL-X L sequesters BAK in resting platelets
To investigate which members of the BCL2 family were expressed in platelets, we analyzed platelet lysates from six different healthy donors ( Figure 6A ). Amongst the anti-apoptotic BCL2 proteins, only BCL-X L was expressed at detectable levels in platelets, suggesting that BCL-X L is the main target of ABT-737 and ABT-263 in platelets. BAX and BAK were both expressed, although to varying levels in the individual samples. Amongst the BCL2 homology domain 3 (BH3)-only proteins, BID was highly expressed, whereas NOXA, BAD and PUMA were not detectable. There was some reactivity with the BIM antibody, however, the resulting bands did not correspond to the For
Discussion
In this study we investigated the consequences of BCL2-inhibition in platelets. Owing to the shared characteristic of PS exposure, platelet apoptosis and activation are often considered related processes.
In contrast to apoptosis induced by BCL2-inhibition, platelet activation induced by the thrombin receptor agonist TRAP, the collagen peptide-mimetic CRP-XL, or the calcium ionophore A23187 led to PS exposure and was accompanied by aggregation, increased fibrinogen binding and rapid exposure of P-selectin, but did not involve caspase activation or cytochrome c release (Figures 2 and   3 ). Our results indicate that mitochondrial changes and caspase activation are not required for platelet activation, although we cannot exclude that these may occur later during prolonged activation or as bystander effects. Apoptosis is defined as a strictly caspase-dependent process. 34 Our data do not support an involvement of apoptosis in platelet activation but rather show that platelet apoptosis as induced by BCL2-inhibition is clearly distinct from platelet activation, in line with a previous report.
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Notably, PS externalization resulting from ABT-263-and ABT-737-induced apoptosis or from platelet activation both resulted in an increased thrombin generation ( Figure 3A ), confirming that PS exposure is directly linked to promotion of hemostasis irrespective of the pathways leading to PS externalization. However, the lack of P-selectin expression and the de-regulation of integrin-ligand interactions following BCL2-inhibition suggests that platelets would not become actively incorporated into a thrombus and therefore their thrombotic effect will be marginal in vivo.
To emphasize further the different pathways resulting in platelet activation or apoptosis our data demonstrate unequivocally that despite the increased thrombin generation ( Figure 3A) , apoptosis inhibits the subsequent response of platelets to their physiological agonists ( Figure 3B-D) . It is interesting to consider these findings in the context of observations made in stored platelets. In platelet concentrates stored for transfusion, apoptosis is increased over storage time. 19 Simultaneously, platelets become less responsive to their physiological agonists, a phenomena referred to as the platelet storage lesion. 35 Interestingly, the depletion of intracellular calcium observed upon BCL2-inhibition ( Figure 4 ) provides a novel mechanistic explanation for the repressed platelet activation.
Several BCL2 proteins like BCL-X L localize to the ER and have been implicated in calcium homeostasis in multiple ways. Notably, inhibition of BCL2 proteins has been previously shown to result in calcium depletion in pancreatic and leukemia cells. 36,37 Since ABT-737-induced apoptosis in platelets was not affected by chelation of extracellular calcium, 24 it is possible that the effect of BCL2/BCL-X L -inhibition on calcium is unrelated and independent of its apoptosis-inducing effects.
The ultrastructural characteristics of apoptotic platelets are not, as yet, well defined. Cytoplasmic condensation and budding, to yield microparticles, have been associated with apoptosis in aging platelets in stored concentrates, 18 but these platelets have also undergone a degree of activation during their preparation, which increased during storage in parallel with their decline into an apoptotic-like 38 However, morphological changes similar to those observed in our study were also reported during apoptosis in platelets aged in vitro which was also accompanied by a reduced aggregatory response.
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Exposure of patients to ABT-263 results in thrombocytopenia during the first 4 weeks of treatment. 12, 13 In the current clinical studies, this problem is circumvented by giving the patients a low priming dose of ABT-263 (100 mg) for 7-14 days before starting with the full therapeutic dose (e.g.
mg
). This priming dose is sufficient to induce a mild thrombocytopenia due to selective apoptosis of older platelets and supposedly results in the generation of an overall younger platelet population, more resistant to the drug thereby allowing dose escalation. 12, 14 In this study, we show for the first time that reticulated human platelets are significantly less susceptible to ABT-263 induced apoptosis (Figure 7) , providing an explanation for the generation of an overall younger platelet population following treatment with ABT-263. Younger platelets are generally thought to be more active than older platelets, 40 although direct evidence for this comes mainly from studies in animal models. 41 It is possible that in patients treated with ABT-263 the lack of platelet numbers and the inhibition of platelet activation in apoptotic platelets might be compensated by a higher activation response in the remaining younger platelets.
The reduced susceptibility of young platelets may be due to an enhanced expression of the drug target A desirable property for any anticancer agent is selective toxicity exhibited against the tumor cells compared to the cells/tissue displaying dose-limiting toxicity. In this regard, no difference in sensitivity of CLL cells and platelets to ABT-737 was observed, whereas platelets were clearly more sensitive to ABT-263 than CLL cells ( Figure 1E-F) . However, this apparent lack of selectivity is in part overcome by the administration of a low priming dose of ABT-263 to patients as discussed above. In CLL cells, the main target of ABT-737 and ABT-263 is BCL2, since circulating CLL cells display very little BCL-X L but overexpress BCL2. In platelets however, the main target of these drugs is BCL-X L , since BCL2 and BCL-w are not expressed at detectable levels ( Figure 6A ). Hence a selective antagonist of BCL2 that does not inhibit BCL-X L could potentially circumvent thrombocytopenia and be used at higher doses, which might be more effective in leukemia therapy. For 
